A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Key Inclusion Criteria: * Chinese Postmenopausal women with ER+ HER2- locally advanced, recurrent, or metastatic breast cancer. Locally advanced breast cancer must not be amenable to curative treatment by surgery or radiotherapy. * Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer * Postmenopausal women. Postmenopausal status was defined either by: * Prior bilateral oophorectomy * Or age ≥60 * Or age \< 60 and amenorrhea for 12 or more months * Recurrence or progression on prior NSAI was defined as: * Recurrence while on, or within one year (12 months) of end of adjuvant treatment with letrozole or anastrozole * Or Progression while on or within one month (30 days) of the end of prior treatment with letrozole or anastrozole * Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrollment * Patient had as per RECIST 1.1 * measurable disease or non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease. * non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease. * Patient was able to swallow and retain oral medication * Patient met the hematologic and biochemistery laboratory values at the screening visit * Patient had a WHO performance status ≤2 * Written informed consent obtained prior to any screening procedures Exclusion Criteria: * HER2-overexpressing patients by local laborat…